Mostrar el registro sencillo del ítem

Is the treatment of Enterobius vermicularis co-infection necessary to eradicate Dientamoeba fragilis infection?

dc.contributor.authorBoga J.A.
dc.contributor.authorRojo S.
dc.contributor.authorFernández J.
dc.contributor.authorRodríguez M.
dc.contributor.authorIglesias C.
dc.contributor.authorMartínez-Camblor P.
dc.contributor.authorVázquez F.
dc.contributor.authorRodríguez-Guardado A.
dc.date.accessioned2020-09-02T22:13:32Z
dc.date.available2020-09-02T22:13:32Z
dc.date.issued2016
dc.identifier10.1016/j.ijid.2016.05.027
dc.identifier.citation49, , 59-61
dc.identifier.issn12019712
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3782
dc.descriptionObjectives: Dientamoeba fragilis is a pathogenic protozoan of the human gastrointestinal tract with a worldwide distribution, which has emerged as an important and misdiagnosed cause of chronic gastrointestinal illnesses such as diarrhea and 'irritable-bowel-like' gastrointestinal disease. Very little research has been conducted on the use of suitable antimicrobial compounds. Furthermore, higher rates of co-infection with Enterobius vermicularis have been described, suggesting that E. vermicularis could influence the treatment of D. fragilis-infected patients. To study this, the treatment of E. vermicularis and D. fragilis co-infected patients was evaluated. Methods: Forty-nine patients with a D. fragilis infection, including 25 (51.0%) patients co-infected with E. vermicularis, were studied. All of them were treated with metronidazole. Patients with E. vermicularis co-infection and/or an E. vermicularis-positive case in the family were treated with mebendazole. Results: Metronidazole treatment failure was significantly more frequent in patients with E. vermicularis co-infection and in patients with children in the family. Conclusions: Co-infection with E. vermicularis may act as a factor favoring D. fragilis infection by preventing eradication measures. This suggests that both parasites should be treated simultaneously. © 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
dc.language.isoen
dc.publisherElsevier B.V.
dc.subjectDientamoeba fragilis
dc.subjectEnterobius vermicularis
dc.subjectMetronidazole
dc.subjectParasite infection
dc.subjectTreatment
dc.subjectmebendazole
dc.subjectmetronidazole
dc.subjectparomomycin
dc.subjectanthelmintic agent
dc.subjectantiprotozoal agent
dc.subjectmebendazole
dc.subjectmetronidazole
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectasymptomatic disease
dc.subjectchild
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectconsultation
dc.subjectdientamoebiasis
dc.subjectdrug treatment failure
dc.subjectenterobiasis
dc.subjectEnterobius vermicularis
dc.subjecteradication therapy
dc.subjectfemale
dc.subjecthuman
dc.subjectimmigrant
dc.subjectmale
dc.subjectmixed infection
dc.subjecttreatment response
dc.subjectanimal
dc.subjectCoinfection
dc.subjectDientamoeba
dc.subjectdientamoebiasis
dc.subjectdrug effects
dc.subjectenterobiasis
dc.subjectEnterobius
dc.subjectfeces
dc.subjectmiddle aged
dc.subjectparasitology
dc.subjectphysiology
dc.subjectpreschool child
dc.subjectyoung adult
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAnimals
dc.subjectAnthelmintics
dc.subjectAntiprotozoal Agents
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectCoinfection
dc.subjectDientamoeba
dc.subjectDientamoebiasis
dc.subjectEnterobiasis
dc.subjectEnterobius
dc.subjectFeces
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMebendazole
dc.subjectMetronidazole
dc.subjectMiddle Aged
dc.subjectYoung Adult
dc.titleIs the treatment of Enterobius vermicularis co-infection necessary to eradicate Dientamoeba fragilis infection?
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84975495134.pdf
Tamaño:
3.880Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem